Today Cleveland Biolabs Incorporated (NASDAQ:CBLI) Reported Decrease in Shorted Shares

September 17, 2017 - By Richard Conner

 Today Cleveland Biolabs Incorporated (NASDAQ:CBLI) Reported Decrease in Shorted Shares

Investors sentiment decreased to 0.8 in 2016 Q4. Its down 0.45, from 1.25 in 2016Q3. It turned negative, as 3 investors sold Cleveland BioLabs, Inc. shares while 2 reduced holdings. 2 funds opened positions while 2 raised stakes. 208,325 shares or 38.86% less from 340,762 shares in 2016Q3 were reported.
Us Bancorporation De stated it has 100 shares or 0% of all its holdings. Morgan Stanley reported 1,050 shares stake. Bancshares Of America Corp De stated it has 0% of its portfolio in Cleveland BioLabs, Inc. (NASDAQ:CBLI). Kcg Holdings holds 31,144 shares. Blackrock Fund Advsrs stated it has 0% of its portfolio in Cleveland BioLabs, Inc. (NASDAQ:CBLI). Bankshares Of Montreal Can accumulated 31 shares or 0% of the stock. Geode Cap Management Limited Com holds 16,688 shares or 0% of its portfolio. Grp Incorporated One Trading Ltd Partnership accumulated 68 shares. Winfield Associate Inc has invested 0% in Cleveland BioLabs, Inc. (NASDAQ:CBLI). Deutsche State Bank Ag owns 0% invested in Cleveland BioLabs, Inc. (NASDAQ:CBLI) for 4 shares. Manufacturers Life Insurance Communication The invested in 34 shares. Susquehanna Gru Llp accumulated 22,216 shares. Moreover, Vanguard Grp Inc Inc has 0% invested in Cleveland BioLabs, Inc. (NASDAQ:CBLI) for 82,203 shares. Blackrock Advisors Lc invested 0% of its portfolio in Cleveland BioLabs, Inc. (NASDAQ:CBLI). Renaissance Technologies Ltd Co accumulated 11,916 shares.

The stock of Cleveland Biolabs Incorporated (NASDAQ:CBLI) registered a decrease of 40.87% in short interest. CBLI’s total short interest was 56,000 shares in September as published by FINRA. Its down 40.87% from 94,700 shares, reported previously. With 28,000 shares average volume, it will take short sellers 2 days to cover their CBLI’s short positions. The short interest to Cleveland Biolabs Incorporated’s float is 1.96%.

The stock decreased 4.92% or $0.15 on September 15, reaching $2.9. About 10,991 shares traded. Cleveland BioLabs, Inc. (NASDAQ:CBLI) has risen 63.33% since September 17, 2016 and is uptrending. It has outperformed by 46.63% the S&P500.

Cleveland BioLabs, Inc. is a biopharmaceutical company. The company has market cap of $32.71 million. The Firm is engaged in developing approaches to activate the immune system and address serious medical needs. It currently has negative earnings. The Company’s platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology.

More notable recent Cleveland BioLabs, Inc. (NASDAQ:CBLI) news were published by: Investorplace.com which released: “Cleveland BioLabs, Inc. (CBLI) Stock Tacks On Another 40%-Plus” on April 19, 2017, also Quotes.Wsj.com with their article: “Cleveland BioLabs Inc.” published on February 11, 2011, Seekingalpha.com published: “Cleveland BioLabs: A Reverse Split Low Floater With Catalysts” on March 11, 2015. More interesting news about Cleveland BioLabs, Inc. (NASDAQ:CBLI) were released by: Streetinsider.com and their article: “Cleveland Biolabs (CBLI) Reports Reverse Stock Split” published on January 27, 2015 as well as Marketwatch.com‘s news article titled: “2.90” with publication date: December 22, 2009.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.